Log in

Member Log In

News from our community

  • 30 Nov 2020 1:24 PM | Deleted user

    TUSCALOOSA, Ala. – Three professors specializing in biomedical sciences, biochemistry and bioengineering will join The University of Alabama during the upcoming spring semester, boosting research and innovation in novel design and engineering of advanced drug delivery systems.

    Dr. Ravi Kumar will be a professor in the College of Community Health Sciences with an adjunct appointment in the College of Engineering’s Department of Chemical and Biological Engineering. Internationally recognized for his significant contributions to nanomedicine research with applications for the treatment of human health and diseases, Kumar will also lead the convergent bioscience and medicine initiative under the Alabama Life Research Institute.

    Along with Kumar, Drs. Meenakshi Arora and Raghu Ganugula will join CCHS as associate professor and assistant professor, respectively. Arora researches the development of biomaterials for therapeutic applications, specifically for autoimmune and inflammatory disease conditions. Ganugula has expertise in biotechnology and pharmacological testing of novel bioactives and drug delivery systems.

    The Office for Research and Economic Development, the Office for Academic Affairs and CCHS partnered in support of the research group’s move to UA.

    “These three outstanding researchers bring a wealth of experience that will advance the University’s research enterprise through collaboration with our existing faculty while enriching the experience of our students,” said Dr. Russell J. Mumper, UA vice president for research and economic development. “They are among the world leaders working in the critical nexus of bioscience and medicine, and they will continue tackling some of the greatest challenges in improving human health.”

    The team will join UA from the Texas A&M University College of Pharmacy, where Kumar leads the premier laboratory in the world in nanotechnology-based oral drug delivery systems. The team currently has about $5.8 million in sponsored research projects, including three Research Project Grants, also known as R01s, from the National Institutes of Health.

    “The College of Community Health Sciences is committed to improving care and treatment for those suffering medically, and this team’s ingenuity in targeting drug delivery furthers and expands our mission and opportunity for collaboration that brings benefits to our faculty and clinical professionals,” said Dr. Richard Friend, CCHS dean.

    Their lab and convergent bioscience and medicine initiative will be established in the AIME Building as part of ALRI, which brings together researchers from across campus to study problems that directly affect the health and well-being of individuals and communities in Alabama, as well as across the nation and world.

    “Advancing solutions in biosciences requires interdisciplinary teams, and the addition of this distinguished group brings another dimension to UA’s ability to better the human condition through new intellectual and technical resources,” said Dr. Sharlene Newman, ALRI executive director.

    Kumar works with basic and clinical scientists in establishing novel drug delivery mechanisms and their application to inflammatory, infectious and vascular disease conditions, and his published research is widely followed by other researchers in the field.

    He was first to propose and demonstrate a non-competitive active targeting nanosystem and its application to diseases. His lab employed this platform in the treatment of difficult to treat diseases such as lupus, diabetes complications and intraocular inflammation in rodent and canine models respectively. His work has advanced fundamental understanding of blood-intestine and other biological barriers and has led to the development of two patents. These technologies have facilitated industry collaborations, as well as the formation of a spinoff company

    In February, Kumar will be inducted into the American Association for the Advancement of Sciences for his contributions to drug delivery. He is also a Foreign Fellow with the European Academy of Sciences, and Fellow with the American Association of Pharmaceutical Sciences, and has received a number of other national and international awards.

    His tenure at Texas A&M began in 2013 after about five years as a professor at the University of Strathclyde in the United Kingdom. He was also an assistant professor at the National Institute of Pharmaceutical Education and Research in India, and a research fellow at Saarland University in Germany.

    Kumar earned a doctorate in drug delivery from the Indian Institute of Technology Roorkee in 2000, a masters of applied chemistry from Devi Ahilya Vishwavidyalaya and a bachelor’s degree in physical sciences from Nagarjuna University.

    Arora is an assistant professor of research at Texas A&M, where she has also been a research scientist. Arora has been an integral member of the research team with Kumar at previous posts, including post-doctoral work in other labs. She earned a doctorate in chemistry in 2001 and a masters of organic chemistry from the Indian Institute of Technology Roorkee as well as a bachelors of chemistry, zoology and botany from Chaudhary Charan Singh University.

    At Texas A&M, Ganugula is an assistant professor of research and was previously an assistant research scientist and postdoctoral researcher. He graduated in 2011 with a doctorate in biotechnology from Central Institute of Fisheries Technology in India, a masters in biotechnology from Andhra University and a bachelors of chemistry, botany and zoology from A.M.A.L. College.

    The University of Alabama, the state’s oldest and largest public institution of higher education, is a student-centered research university that draws the best and brightest to an academic community committed to providing a premier undergraduate and graduate education. UA is dedicated to achieving excellence in scholarship, collaboration and intellectual engagement; providing public outreach and service to the state of Alabama and the nation; and nurturing a campus environment that fosters collegiality, respect and inclusivity.

    Additional news about The University of Alabama can be found at:

  • 24 Nov 2020 9:00 AM | Deleted user

    A University of Alabama at Birmingham (UAB) faculty member has founded a company to tackle the pervasive problems faced with respiratory diseases.

    ResBiotech, a cardio-respiratory health innovation platform company, was recently launched by Dr. Charitharth Vivek Lal to target respiratory diseases like chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma and others. Affecting more than 20 million people in the United States alone, respiratory diseases represent a $50 billion market and show no signs of decreasing.

    ResBiotech, which was launched with UAB’s Bill L. Harbert Institute for Innovation and Entrepreneurship and is working with the Birmingham Business Alliance (BBA) and other partners to seek investors, will revolutionize the future of patient care and strengthen Birmingham’s health care and entrepreneurial ecosystems, said Jon Nugent, vice president of innovation and technology for the BBA.

    “Birmingham is the right place to launch this type of company because of the continual health care innovation that is one of our region’s trademarks,” said Nugent, who has worked with Dr. Lal for over a year. “There is continued and widespread interest in state-of-the-art health care innovation. Dr. Lal’s vision, coupled with support from UAB and local stakeholders, could prove to be pathbreaking for Birmingham and Alabama as a whole.”

    Using medical technologies to solve major health challenges, its first product, ResBiotic – currently in preclinical development – will serve as a wellness supplement for respiratory illnesses in people of all ages.

    “The company will be focused on the invention, creation and monetization of proprietary medical technologies that solve major health challenges,” Lal said.

    Dr. Sanjay Singh, a local entrepreneur, former UAB faculty and a member of the BBA’s Executive Committee, will serve as the strategic business adviser for ResBiotech. In addition, a Scientific Advisory Board will be created for the company.

    “ResBiotech will be an innovation, investment and commercialization vehicle, with access to world-class researchers and facilities locally,” said Singh. “I foresee ResBiotech positioned to become a national leader in the cardio-respiratory innovation industry, one that could revolutionize patient care in the future.”

    Dr. Kathy Nugent, executive director of the Bill L. Harbert Institute for Innovation and Entrepreneurship at UAB, emphasized Birmingham’s entrepreneurial ecosystem and Dr. Lal’s board service to Urgent Care for Children, another Birmingham startup that is quickly growing.

    “It’s exciting to see research born in the university spin out and grow in Birmingham, as our ecosystem is poised for cultivating innovative concepts,” said Nugent.  

    Click here to learn more.

  • 24 Nov 2020 8:53 AM | Deleted user

    November 18, 2020 (Huntsville, AL) – Three scientists from the HudsonAlpha Institute for Biotechnology were named to the annual Highly Cited Researchers™ 2020 list from Clarivate. The list identifies scientists and social scientists who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade. Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.

    By nature, research builds upon past knowledge. When reporting new research, scientists place their work in the proper context with respect to the past work upon which it builds. This is done by referencing sources of information, also known as citations.

    In the research community, citations serve not only as performance indicators for individual scientists or fields of study, but also to create webs of knowledge. Citing other research helps to validate the new work and explain how it fits into, or challenges, the current knowledge in the field.

    HudsonAlpha has a strong record of making significant contributions to the research community. This is the seventh year in a row that at least three HudsonAlpha scientists have been named on the Highly Cited Researcher list. This speaks volumes to the expertise and respect that these scientists have in their field of study and beyond.

    “HudsonAlpha’s outstanding track record of Highly Cited Researchers is a testament to the impactful foundational research that our Institute prides itself on,” says Rick Myers, PhD, President and Science Director and M. A. Loya Chair in Genomics at the HudsonAlpha Institute for Biotechnology. “Collaborative research is an important pillar on which the spirit of HudsonAlpha was built, and we are proud that our scientists are able to be active contributors to the open flow of research and information in the genomics field.”

    Past HudsonAlpha faculty included on the Highly Cited Researcher list include Myers, Devin Absher, PhD, Greg Cooper, PhD, Jane Grimwood, PhD, and Jeremy Schmutz.

    The three scientists named to the 2020 list are:

    • Faculty Investigator Jane Grimwood, PhD – Cross-field
    • Faculty Investigator Jeremy Schmutz – Plant and Animal Science
    • Jerry Jenkins, PhD – Cross-field  

    Grimwood and Schmutz serve as the co-directors of the HudsonAlpha Genome Sequencing Center. Together with their research teams, they have sequenced well over 150 de novo plant genomes, both for their own research projects and collaborative projects. The de novo plant genomes serve as a foundation for genomic and functional plant research, meaning that hundreds of scientists rely on and utilize the reference genomes created by Grimwood and Schmutz’s group.

    Because of their expert status in the plant genomics field, Grimwood and Schmutz are no strangers to the Highly Cited Researcher List, both having been named to the list several times before. In fact, Schmutz has made the list every year since its inception in 2014.

    Although Jenkins is a newcomer to the Highly Cited Researcher list this year, he has been a critical part of the Genome Sequencing Center team for nearly a decade. He serves as the Genome Analysis Group Leader and is involved in the generation and improvement of de novo plant genomes.

    “Working in the Genome Sequencing Center with Jane and Jeremy over the past decade has given me the opportunity to participate in high-quality research and collaborate with dozens of research groups to help address important questions pertaining to plant science,” says Jenkins. “It is rewarding for me personally to see that our peers recognize the impact the group is having in plant genomics, and we plan to continue to make high quality contributions to address questions in plant science."

    Grimwood, Schmutz and Jenkins are three of 6,167 researchers from more than sixty countries and regions recognized this year, 2,650 of which reside in the United States. They are also joined by 26 Nobel Laureates.

    “In the race for knowledge, it is human capital that is fundamental and this list identifies and celebrates exceptional individual researchers who are having a great impact on the research community as measured by the rate at which their work is being cited by others,” said David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate.

    The full 2020 Highly Cited Researchers list and executive summary can be found online here.


    About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit

  • 23 Nov 2020 9:11 AM | Deleted user

    State of Alabama, HudsonAlpha and biotech companies working to track COVID-19 transmission

    November 23, 2020 (Huntsville, Ala.) – HudsonAlpha Institute for Biotechnology today announced the ongoing efforts in support of Alabama Governor Kay Ivey’s work to respond to and mitigate COVID-19. Through Alabama’s Coronavirus Relief Fund and the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), $600,000 has been allocated to HudsonAlpha to perform genomic sequencing on positive SARS-CoV-2 samples from people across the state of Alabama.

    “All of us at HudsonAlpha are grateful to the state of Alabama for this support to help strengthen our state’s response and planning for this pandemic," said Rick Myers, PhD, President, Science Director and M. A. Loya Chair in Genomics at the HudsonAlpha Institute for Biotechnology. “HudsonAlpha’s genomic research scientists are fully committed to combating this deadly virus.”

    There are multiple goals with this COVID-19 initiative including identifying different strains of SARS-CoV-2 virus from all regions of the state, generating longitudinal data to determine changes in the SARS-CoV-2 virus during the pandemic; identifying possible sources of new hotspots of infection in Alabama; surveying for possible emerging strains of virus which could have implications for vaccine development and vaccine efficiency; and adding an Alabama perspective to national and global COVID-19 initiatives through sequencing data generated in the state. The information generated will be provided to the Alabama Department of Public Health and other parties that have critical roles in responding to the pandemic.

    Leading this project is co-director of HudsonAlpha’s Genome Sequencing CenterJane Grimwood, PhD. “Through this initiative with the state, HudsonAlpha aims to provide actionable information to help the collective efforts of policymakers and frontline workers in the fight against the pandemic,” said Grimwood.

    HudsonAlpha is currently working with Diatherix-Eurofins Laboratories (HudsonAlpha resident associate company) as provider of the COVID-19 samples. HudsonAlpha is engaging other sources to provide additional samples to extend geographic and demographic coverage throughout the state.




    About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit

  • 14 Nov 2020 7:32 AM | Deleted user

    On the closing day of the first annual Southeast Life Sciences conference, the AdvanSE Life Sciences Conference, we want to congratulation the winners of our awards and PitchRounds.

    Southeast Life Sciences awards include awards for best initial funding, best venture funding, best strategic partnership, best M&A, and best IPO. The winners of these are as follows. These awards go back more than a decade from both Southeast BIO and the Southeast Medical Device Association prior to the merger. Some of the biggest success stories from the southeast have been included in these awards and we expect the same big things with our winners this year!

    • For best Initial Funding (seed or angel), the winner is Acclinate Genetics, from Huntsville, Alabama.
    • For best Venture Funding (>$1mm from institutional investors), the winner is Embody Inc., from Norfolk, VA
    • For best Strategic Partnership, the winner is SiO2, of Auburn, Alabama
    • For best M&A, the award goes to AskBio, from RTP, NC, which was acquired by Bayer AG.
    • For best IPO, the award goes to Shattuck Labs, from Durham, NC and Austin, TX

    SE PitchRounds this year took in more than 70 applications from across the region for only 22 slots. These 20 companies represented the most exciting technologies and some of the most experienced entrepreneurs in the region. From the initial 22, we selected four finalists that presented on the closing day of the conference. The finalists were Embody, Inc., MoterumHeamGen, and Stuart Therapeutics.

    The winners from the bipharma/diagnostic group was Stuart Therapeutics.

    The winner from  the medtech/digital group was Embody, Inc.

    Congratulations to Everyone!

  • 12 Nov 2020 7:57 AM | Deleted user

    This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. The person responsible for making this announcement is David Bishop, Director of Investor Relations.

    Croda International Plc (“Croda” or “the Group”), the speciality chemical company that uses smart science to create high performance ingredients and technologies that improve lives, today announces that it has recently entered into an agreement with Pfizer Inc. to supply novel excipients used in the manufacture of a COVID-19 vaccine candidate. The contract with Pfizer runs for five years and awards Croda an initial supply contract for four component excipients used in the production of the vaccine candidate for the first three years of the contract. Demand remains subject to relevant approvals.

    Croda’s recently acquired subsidiary, Avanti Polar Lipids, Inc. (“Avanti”), specialises in the development and production of high-purity lipids, to produce research and clinical trial quantities of excipients in order to stabilise formulations and enable delivery into the body by parenteral mechanism (injection) for drug and vaccine applications. Croda’s existing health care business has a 20-year track record in developing IP-rich, innovative technologies for drug delivery systems for the pharmaceutical industry and has been working with Avanti, prior to and since its acquisition by Croda, to refine the complex processes involved in achieving the volumes of high-purity excipients required by its pharmaceutical customers. Croda has reprioritised investment, resources and other projects across the Group over the last few months to focus on the delivery of this project.

    Commenting on the new contract, Steve Foots, Chief Executive Officer, said:  

    “I’m very proud of Croda’s involvement in the battle to fight the most significant pandemic that we have seen in a generation. The application of our innovative capabilities is testament to the strong progress we have made to create industry-leading drug delivery systems, focused on developing speciality excipients and adjuvants to improve the effectiveness and stability of complex drug actives and vaccines. It is another example of why our Purpose - Smart Science to Improve Lives – sits at the heart of our strategy and will continue to drive our priorities and ambitions in the years ahead.”

  • 9 Nov 2020 10:29 AM | Deleted user

    Nonprofit Operations & Marketing Internship 

    You are intrinsically curious about Alabama’s bioscience industry and are motivated to promote the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience. Under the guidance and supervision of the executive director,  you will support back office operations, marketing, and event planning to further the mission of BIO Alabama, the state affiliate of Biotechnology Innovation Organization (BIO) and the leading advocate for Alabama’s bioeconomy. BIO Alabama is a membership-based professional organization representing the state on a national and international stage. Your role as an intern will be to support the executive director in further connecting our bioscience ecosystem. This internship is for college credit and will follow your instructor’s internship guidelines including minimum hour requirements and deliverables. 

    What you will do

    • Prepare bi-weekly e-newsletter drafts for executive director’s review and approval.

    • Assist with weekly social media posts and engagement.

    • Coordinate all details of events (both virtual and in person) including speaker invitations, speaker planning and  preparation, promotion, day of event setup, and event attendee follow-up.

    • Conduct market research as needed to better understand the State’s bioscience ecosystem and it’s assets. 

    • Update and maintain data in customer management systems (CRM)

    • Participate in weekly planning calls with the executive director.

    What you already have

    • Interest in learning marketing and social media for a state-wide, nonprofit, professional organization. 

    • Interest in learning how to plan and implement small/medium scale events.

    • Experience conducting research and possess strong written and oral communications skills. 

    • Ability to navigate a wide variety of business and social settings and enjoy taking the message of BIO Alabama to individuals and organizations not yet familiar with its mission.

    Submit PDF file of Cover Letter & Resume to: Sonia Robinson, Executive Director

    DEADLINE: January 29, 2021

  • 3 Nov 2020 8:41 AM | Deleted user

    HUNTSVILLE, Ala. – October 15, 2020 – Kailos Genetics announces the launch of Assure Sentinel, a first-of-its-kind workplace viral suppression program that tests organizations for COVID-19 on a frequent and recurring basis.

    The Assure Sentinel program reduces the challenges of COVID-19 testing in the workplace. Samples are acquired using the easy and painless ViraWash™ saliva collection system, eliminating the need for nasopharyngeal swabs. Additionally, testing is performed with ViralPatch™, the company’s proprietary viral capture and sample pooling methodology, and next generation DNA sequencing to decrease costs and increase testing sensitivity.

    “Pooling dozens of samples together has been standard in blood banking for decades. The Assure Sentinel program is helping to suppress COVID-19 and returning people to the workplace,” says Brian Pollock, Chief Executive Officer for Kailos Genetics.

    Regular COVID-19 testing can mean a reduction in employee anxiety and a rise in confidence and productivity. "Safety is, and has always been, our number one priority during the pandemic, and the Assure Sentinel program is helping us continue to ensure the safety and well-being of our employees," said Julia Michaux-Watkins, Director of Human Resources at HudsonAlpha.

    Kailos is offering the workplace testing program to companies, non-profit organizations and schools directly and via partnerships with healthcare organizations. The first partnerships announced include Huntingdon College (Montgomery, AL) and the HudsonAlpha Institute for Biotechnology (Huntsville, AL).

    “Since the beginning of the pandemic, Huntingdon College identified access to testing as a key element to our ability to responsibly reopen our campus to our students, faculty and staff for the fall. We have been fortunate to find an Alabama-based partner to provide a reasonably priced, efficient testing option, which has been critical in successfully mitigating the spread of COVID-19 on our campus,” says Jay Dorman, Treasurer and Senior Vice President for Institutional Effectiveness, Planning and Administration at Huntingdon College.

    For more information on Kailos Genetics Assure Sentinel program, email

    Kailos Genetics is a leader in innovative, cost-effective solutions that make genetic screening accessible to everyone.  Kailos provides genetic and COVID-19 testing through partnerships with physicians, health systems and employers around the world.


  • 3 Nov 2020 8:32 AM | Deleted user

    Huntsville, AL  (October 19)  – GeneCapture, a company developing products for commercial and government applications for point of care diagnostics, announced today the world’s first multi-pathogen identification using non-amplified RNA detection. Its 1 hour ‘sample to answer’ CAPTURE PLATFORM™ is on track for commercialization within two years.

    “We made history today – this is the first time an automated rapid pathogen identification has been reported directly from the sample, with no modification or amplification of its genetic source, in about an hour,” said GeneCapture CEO Peggy Sammon. “We envision a future where finding out why you are sick can be solved almost anywhere, in an hour, and without being chained to a lab. Infection detection will soon be portable, fast, and inexpensive. Just as the shift from relying on central computers to desktop and handheld devices enabled entirely new markets, so will decentralized, portable multi-pathogen infection detection.”

    GeneCapture’s unique disposable cartridge enables its point of care vision for rapid, inexpensive multi-pathogen identification. Whether the illness is bacterial, viral, fungal or protozoan, a single test will pinpoint the cause. The novel technology consolidates sample prep and molecular signature detection in one plastic cartridge with a ‘one button’ portable reader.

    Rick Myers, PhD, President, Science Director and M. A. Loya Chair in Genomics at HudsonAlpha says, “GeneCapture’s approach, an array-based genetic fingerprint based on direct RNA hybridization, is an innovative way to simplify the process and cost of responding to infections. Their recent demonstration of Sample-to-Answer pathogen identification is a major milestone for this industry.”  

    The significance of a non-amplified solution is in the logistics. Without a need for enzymes, the test cost and complexity drop dramatically, allowing non-medical personnel to perform multi-pathogen tests without access to a lab. This ease of use will open up new markets for infection detection at schools, day care centers, clinics, veterinary offices, nursing homes, airports and field hospitals. The cost per test is forecasted at only $20 for each disposable hand-sized cartridge.

    GeneCapture’s future products will screen a human/animal sample for up to 200 pathogens in less than an hour.  Their CAPTURE PLATFORM™ (Confirming Active Pathogens Through Unamplified RNA Expression) requires neither enzymes nor refrigeration and will have an expected shelf life of over a year. The product is envisioned for point of care applications including remote rural health and military operations. 

    The initial molecular binding concept was conceived at The University of Alabama in Huntsville (UAH) and licensed to GeneCapture, which is an associate company at the HudsonAlpha Institute for Biotechnology - one of the world’s leading genomics centers. The company has since filed an additional 11 patents, built prototypes, and performed successful pre-clinical validation tests. In addition to the commercial applications, the company has been awarded multiple Department of Defense contracts to mature the technology for potential far-forward military operational use.

    The closed cartridge accepts a direct sample (urine, blood, swab) and then concentrates and exposes the pathogen’s RNA fragments to the custom DNA probes on an array. Once the RNA is captured, the specific probes activate an optical sensor. The pattern across the array identifies the pathogen. Limits of detection have been validated and are currently clinically relevant for most bacterial infections, and are being optimized for viral infections.

    Louise O’Keefe, PhD, Director of the Faculty and Staff Clinic at UAH, and an advisor to GeneCapture says, “Our industry needs a breakthrough in turnaround time for diagnostic results.  GeneCapture’s approach could transform that challenge we deal with every day.”

    The GeneCapture team has briefed the Food and Drug Administration (FDA) on its approach and has begun the process to prepare for the clinical testing required for FDA clearance. 

    The company is in discussions with industry leaders for various applications in health care infection detection. 




    Photo caption: GeneCapture’s disposable cartridge integrates sample prep and pathogen identification in its rapid, portable ‘sample-in answer-out’ pathogen identification platform.

    About GeneCapture: GeneCapture is developing products for commercial and government applications for point of care diagnostics. The company’s patented CAPTURE PLATFORM™ performs direct RNA hybridization to rapidly identify infectious disease organisms from urine, saliva and blood. The ability to detect up to 200 pathogens from a single run at an expected price of $20 sets the CAPTURE PLATFORM™ apart. With the addition of antimicrobial susceptibility testing to their offerings, GeneCapture is in a position to bring the capabilities of a microbiology lab to point of care applications and to underserved locations in the U.S. and around the world. 

    About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit

    About UAH: Launched from America’s quest to conquer space, The University of Alabama in Huntsville is one of America’s premier doctoral-granting, research-intensive universities. Located in the second largest research park in the United States, UAH has robust capabilities in astrophysics, cybersecurity, data analytics, logistics and supply chain management, optical systems and engineering, reliability and failure analysis, rotorcraft and unmanned systems, severe weather, space propulsion, and more. UAH prepares students for demanding positions in engineering, the sciences, business, nursing, education, the arts, humanities, and social sciences.

  • 2 Nov 2020 3:30 PM | Deleted user

    HUNTSVILLE, Ala., October 27, 2020 –Transomic Technologies, a leading functional genomics laboratory located on the campus of the HudsonAlpha Institute for Biotechnology, announced today that it has become a member of’s VIP Program. Only laboratories that achieve a high customer satisfaction rating and that commit to maintaining superior customer service are invited to join the program.

    “ puts our portfolio of cutting-edge functional genomic services in front of thousands of pre-qualified research customers, “said Blake Simmons, CEO of Transomic Technologies. “The platform helps us get the word out about our latest tools and technologies and helps improve our digital reputation through positive reviews for our products, services, and customer support.”

    Transomic Technologies helps life science researchers move their work forward faster by offering genomic tools and services that use next generation strategies such as CRISPR Cas9 gene editing technologies. Transomic works directly with the researcher to understand their goals and to provide the best solutions to accomplish those goals.

    “Transomic Technologies is a rapidly-growing genomics tools company that has built a reputation for offering innovative technologies,” said Kevin Lustig, PhD,’s Founder and CEO. “We are thrilled they have joined with other exceptional laboratories in our VIP Program to offer high-quality, competitively-priced services and a commitment to outstanding customer service.”


    About Transomic: Transomic Technologies offers life science researchers one of the industry’s most comprehensive portfolios of lentiviral-based functional genomics tools. These tools use next generation technologies such as CRISPR-Cas9 to advance discovery research. Transomic uses their genomic tools to accomplish custom service projects for several major pharmaceutical companies, ranging from knockout cell lines to CRISPR screening assays. Learn more at

    About is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk, and provides access to the latest innovative tools and technologies. operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies, the Biotechnology Innovation Organization (BIO) and the US National Institutes of Health (NIH).  Visit to learn more.

    Follow on social media: LinkedInTwitterYouTubeFacebook, and Instagram

    Follow Transomic Technologies on social media: LinkedIn, Twitter, Facebook, and Instagram

Connecting the Bioscience Ecosystem in Alabama

BIO Alabama
P.O. Box 583
Arab, AL 35016

© BIO Alabama

Powered by Wild Apricot Membership Software